Evidence-led peptide reference
Tirzepatide research guide
Updated 10 October 2026 · Editorial standards
A dual GIP and GLP-1 receptor agonist with authorised prescription uses and extensive clinical evidence.
Identity and context
What is Tirzepatide?
Tirzepatide is a synthetic peptide that activates the GIP and GLP-1 receptors. It is the active pharmaceutical ingredient in authorised prescription medicines used for defined indications, subject to eligibility and clinical supervision.
The existence of an approved medicine does not make every product carrying the same name equivalent. Authorised medicines have product-specific controls for manufacture, presentation, supply and monitoring. Research-labelled material must not be represented as interchangeable with a licensed prescription product.
Mechanism under investigation
How is Tirzepatide studied?
GIP and GLP-1 are incretin hormones involved in the body's response to food. Receptor activation can influence glucose-dependent insulin secretion, glucagon signalling, gastric emptying, appetite and satiety. Tirzepatide combines activity at both receptors in one molecule.
Its clinical effects arise from the whole treatment context, including a verified authorised product, appropriate selection, monitoring and management of adverse effects. A mechanism summary is not a self-treatment guide.
Research map
Main areas of interest
Type 2 diabetes
Large clinical programmes have studied glycated haemoglobin, fasting glucose, body weight and comparisons with established treatments.
Weight management
Randomised trials have evaluated weight reduction and cardiometabolic outcomes in adults meeting study eligibility criteria.
Wider metabolic outcomes
Research continues in areas including cardiovascular outcomes, sleep apnoea, liver disease and long-term weight maintenance.
Strength of evidence
What does the evidence actually show?
Evidence is separated by level because a cell experiment, an animal model, a human trial and a regulatory decision answer different questions.
Critical reading
Limitations and unanswered questions
- Benefits and risks depend on indication, eligibility, coexisting conditions and concurrent medicines.
- Common adverse effects are gastrointestinal; important warnings and contraindications belong in the authorised product information.
- Trial outcomes cannot be transferred to an unlicensed or analytically unverified preparation.
- This page explains research and does not replace a prescriber, pharmacist or official patient information leaflet.
Analytical context
What a certificate of analysis can—and cannot—tell you
A certificate of analysis is a report about the particular submitted sample and tests named on that report. It can help document identity, measured amount or purity when suitable methods were used. It does not prove that every batch is identical, that a material is sterile or endotoxin-free, that it is clinically effective, or that it is approved for human use.
No product-specific COA is currently linked to this guide. Absence of a displayed report should not be interpreted as analytical verification.
Learn how to read a peptide COA →Questions answered
Tirzepatide FAQs
Is tirzepatide a GLP-1 medicine?
It activates the GLP-1 receptor, but it also activates the GIP receptor. It is therefore more precisely described as a dual GIP/GLP-1 receptor agonist.
Is tirzepatide the same as retatrutide?
No. Retatrutide adds glucagon-receptor activity and remains investigational, while authorised tirzepatide medicines have defined licensed uses.
Does the published evidence apply to any tirzepatide-labelled item?
No. Clinical evidence relates to the exact medicinal products and protocols studied. Name similarity does not prove pharmaceutical equivalence.
Where should medical-use information come from?
Use the NHS, NICE, the authorised product information and an appropriate healthcare professional.
Primary and authoritative reading
Sources and further reading
Sources are provided so readers can inspect the underlying literature and current official information. Inclusion does not mean every claim in a paper has been independently confirmed.
- NHS tirzepatide overview ↗UK public-health information on authorised use and safety context.
- SURMOUNT-1 trial ↗Peer-reviewed randomised human weight-management trial.
- NICE tirzepatide guidance ↗Current UK technology-appraisal and guidance search.
Source and wording review: 7 October 2026. Prepared with AI assistance; no independent clinical review is claimed. Read the editorial policy or suggest a correction.